Shenzhen Xingchenhai Medical Technology

About Shenzhen Xingchenhai Medical Technology

Shenzhen Xingchenhai Medical Technology, which also operates under the name Macrolux Medical, is a medical technology firm established in October 2020 and based in Shenzhen, China. The company's general manager is Zhang Weiqiang. The founding team is composed of experts with over a decade of experience in product development, global marketing, and production management within the endoscope and minimally invasive surgical device sectors, sourced from prominent medical device companies.

The company's core business is the development and provision of single-use electronic endoscopes and interventional diagnosis and treatment solutions. This focus aims to address the challenges associated with traditional reusable endoscopes, such as the risk of cross-contamination and high acquisition and maintenance costs. By offering disposable alternatives, Macrolux intends to enhance efficiency, reduce costs, and improve patient safety. The business serves healthcare professionals and hospitals worldwide, with a market presence in China, the United States, Europe, Asia-Pacific, and Latin America. Its solutions cater to various medical departments, including urology, respiratory, digestion, gynecology, and airway management.

Macrolux's product portfolio includes a range of single-use digital endoscopes. The CoralView® U series is a flexible ureteroscope designed for urology with features like a 7.5Fr insertion tube. The BubbleViewTM is a single-use digital flexible cystoscope that received FDA 510(k) clearance in June 2024. For gynecology, the SeleneView® disposable hysteroscope, which also has FDA 510(k) clearance, is designed to be used without anesthesia or cervical dilation. The company also produces the LoopView® single-use digital flexible bronchoscope. These devices are supported by the ViewHub® S13 video processor. The company has secured multiple rounds of funding, including a Series A round of nearly CNY 100 million in early 2023 and a Series B+ round in January 2025, to fuel its global expansion and new product development.